Navigation Links
Amicus Therapeutics Announces Third Quarter 2009 Financial Results and Strategic Business Updates
Date:10/29/2009

sease with continued significant investment with the chaperone platform in diseases of neurodegeneration, which continue to yield very exciting near-term and long-term potential value for the Company. The chaperone-ERT combination approach is also one of potentially significant value for Amicus shareholders as a further extension of our technology," said John F. Crowley.

The Company also announced today a work-force reduction of approximately 20 percent, or 26 employees, as a part of a corporate restructuring, with reductions occurring across all levels and organizations within the Company. In addition, Amicus is terminating its relationship with approximately 17 contractors currently working at the Company. Amicus is taking this step to reduce costs and to align its resources with its key strategic priorities. The Company estimates that it will record charges of approximately $0.9 million during the fourth quarter of 2009 for employment termination costs payable in cash in connection with the workforce reduction.

"After extensive review of our business plan, we have made some very difficult decisions to restructure our workforce to best enable us to align the Company around the three key strategic priorities for Amicus going forward," said John F. Crowley. "Specifically, we expect that these changes will enable our current cash to last into the second half of 2011. It is exceptionally difficult to implement these employee changes as so many remarkably dedicated and talented persons, including Jim Dentzer, our Chief Financial Officer, will be leaving Amicus. All of them have contributed significantly to the Company, and I cannot thank them enough for all of their tireless efforts, passion and contributions."

"We are highly confident that with this restructuring and strategic repositioning, we are well poised to maximize shareholder value while ensuring that we deliver on our mission to provide innovative and high quality therap
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... 18, 2014  MEI Pharma, Inc. (Nasdaq: MEIP ... novel therapies for cancer, announced today that Daniel P. ... at BioCentury,s NewsMakers in the Biotech Industry conference ... from the Millennium Broadway Hotel & Conference Center in ... presentation can be accessed at www.meipharma.com . A replay ...
(Date:9/18/2014)... 18, 2014 OMICS Group International ... to participate in the ‘Open Access Week’ by ... OMICS Group Pharma Journals from 20-26th ... the fastest emerging Sciences, accelerating with a tremendous ... across the globe. The industry is gearing with ...
(Date:9/18/2014)... USC have developed a new microscopy technology that ... animals at higher-than-ever resolution. , Dubbed "Complementation Activated ... resolutions that are an order of magnitude finer ... the behavior of biomolecules at the nanometer scale. ... by Nature Communications , the researchers behind ...
(Date:9/18/2014)... City, MX (PRWEB) September 18, 2014 ... in Mexico City, MX. ASEA is the manufacturer of ... and the skin care product, RENU28. , The ... Regional Vice President Duvan Botero, and ASEA Field Leader ... Samuelson holds a PhD in Atomic/Medical Physics from the ...
Breaking Biology Technology:MEI Pharma To Present At BioCentury's NewsMakers Conference 2MEI Pharma To Present At BioCentury's NewsMakers Conference 3Pharma and Omics Journals to Address Global Challenges during Open Access Week 2Pharma and Omics Journals to Address Global Challenges during Open Access Week 3Scientists pioneer microscopy technique that yields fresh data on muscular dystrophy 2Announcing the ASEA Mexico Grand Opening Tour Beginning September 18th 2
... Aug. 18 Sigma-Aldrich® Corporation (Nasdaq: SIAL ... been named Vice President and Chief Information Officer, effective ... lead the Company,s global information systems function and will ... Officer and Chief Administrative Officer. Borg (age ...
... 18 NephRx Corporation today announced that the U.S. ... designation to its lead product NX001 for the prevention ...  NX001 is a kidney growth factor peptide that has ... models of acute renal failure.   "Delayed ...
... FutureFuel Corp. (OTC Bulletin Board: FTFL ) filed ... special cash dividend of $0.20 per share. The ... a special cash dividend of U.S. $0.20 per share on ... 2010. The dividend is payable September 30, 2010. ...
Cached Biology Technology:Sigma-Aldrich Announces Appointment of Magnus Borg as Vice President and Chief Information Officer (CIO) 2NephRx Corp. Receives Orphan Drug Designation for NX001 for Prevention of Delayed Kidney Graft Function 2
(Date:9/18/2014)... the first smartphone app that automatically reveals students, ... other words, your smartphone knows your state of ... how that affects you. , The StudentLife app, ... to their academic performance, also may be used ... monitor mental health, trigger intervention and improve productivity ...
(Date:9/18/2014)... celebrated tonight at the third annual Golden Goose Award ... premature infants and in paving the way for the ... supported by the National Science Foundation, the National Institutes ... be honored at a ceremony at the Library of ... of Congress will be on hand to help present ...
(Date:9/18/2014)... when people are too stressed they are often grouchy, ... Mind Institute (BMI) at EPFL have just highlighted a ... stress and the loss of social skills and cognitive ... synaptic regulatory molecule in the brain. This was revealed ... , Carmen Sandi,s team went to look for ...
Breaking Biology News(10 mins):New Dartmouth smartphone app reveals users' mental health, performance, behavior 2New Dartmouth smartphone app reveals users' mental health, performance, behavior 3New Dartmouth smartphone app reveals users' mental health, performance, behavior 43rd annual Golden Goose award ceremony honors 8 researchers; Unusual work had big results 2How stress tears us apart 2
... April 27 Negotiations broke off early Tuesday morning between Temple ... (PASNAP) following a 14-hour session.  Talks are expected to resume later today at ... Continued progress was reported, but ... , Temple ...
... Holdings, Inc. (NYSE: MDC ) today announced that its board of directors has ... share on the Company,s common stock.  The dividend will be paid on Wednesday, May ... , , ... , , ...
... , April 26 /PRNewswire-Asia/ -- Winner Medical ... "Company"), a leading manufacturer of,medical dressings, medical disposables and ... announced today that it has,priced a public offering of ... of, $6.10 per share. Winner Medical expects to ...
Cached Biology News:M.D.C. Holdings Declares Quarterly Cash Dividend 2Winner Medical Group inc. Prices Offering of 1,380,000 Shares of Common Stock 2Winner Medical Group inc. Prices Offering of 1,380,000 Shares of Common Stock 3Winner Medical Group inc. Prices Offering of 1,380,000 Shares of Common Stock 4
Rabbit polyclonal to Leucyl tRNA synthetase ( Abpromise for all tested applications). Antigen: L930-H1176 denatured human recombinant LRS. Entrez Gene ID: 3926 Swiss Protein ID: Q9P2J5...
Neutrophil cytosol factor 2 (NCF-2) (Neutrophil NADPH oxidase factor 2) (67 kDa neutrophil oxidase factor) (p67-phox) (NOXA2). [Source:Uniprot/SWISSPROT;Acc:P19878] Antigen: Recombinant Protein E...
... Rabbit polyclonal to FANCM ( Abpromise ... Antigen: Synthetic peptide derived from ... Human FANCM. (Note: the amino acid ... available as ab27787 .) ...
Rabbit polyclonal to 13,14 dihydro 15 keto Prostaglandin E2 ( Abpromise for all tested applications)....
Biology Products: